ReviewFrontiers in medicine2026
Biomarkers of pulmonary fibrosis in bronchoalveolar lavage fluid and saliva. Study methods and pathophysiological significance.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This narrative review synthesizes the current evidence of the molecular biomarkers related to pulmonary fibrosis in bronchoalveolar lavage fluid (BALF) and saliva. It has a particular focus on pulmonary fibrosis diseases (IPFs). It provides a detailed description of the pathophysiological bases and clinical relevance of several extracellular matrix (ECM) components and markers of epithelial damage or remodeling. In this review, it is included type I collagen, hydroxyproline, fibronectin, elastin, KL-6 and matrix metalloproteinases (MMPs). Also, the main methodologies used for their detection and quantification are critically reviewed, highlighting their advantages and limitations in each matrix. Exploring the potential alveolus-saliva pathophysiological axis, it is proposed that this disruption of the alveolar-capillary barrier and the increasing vascular permeability may allow high-molecular-weight biomarkers and matrix derived components to reach the saliva. Thereby, it will enable non-invasive monitoring strategies. However, there are not yet studies that simultaneously analyze BALF and saliva in the same patient cohorts together with the lack of standardized protocol for sampling, analytical normalization and salivary reference ranges. Overall, this review identifies key opportunities and knowledge gaps for the development of BALF-saliva multimarker panels with diagnostic, prognostic and treatment-monitoring potential in fibrotic interstitial lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.